683 Capital Management LLC Invests $878,000 in Armata Pharmaceuticals, Inc. $ARMP

683 Capital Management LLC bought a new position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) during the 4th quarter, HoldingsChannel reports. The fund bought 139,860 shares of the company’s stock, valued at approximately $878,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $108,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $177,000. SeaCrest Wealth Management LLC boosted its holdings in shares of Armata Pharmaceuticals by 17.3% during the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after purchasing an additional 6,034 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $284,000. Finally, State Street Corp lifted its holdings in Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after acquiring an additional 10,500 shares during the last quarter. 3.57% of the stock is currently owned by institutional investors and hedge funds.

Armata Pharmaceuticals Trading Up 4.0%

Shares of NYSEAMERICAN ARMP opened at $7.06 on Thursday. Armata Pharmaceuticals, Inc. has a twelve month low of $1.75 and a twelve month high of $16.34. The stock has a fifty day simple moving average of $9.43 and a 200-day simple moving average of $8.40. The stock has a market capitalization of $259.17 million, a PE ratio of -0.91 and a beta of 1.21.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($3.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The firm had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.74 million. On average, equities analysts predict that Armata Pharmaceuticals, Inc. will post -1.88 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright upped their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Zacks Research upgraded Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Armata Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.